×
About 8,945 results

ALLMedicine™ Chronic Myeloid Leukemia Center

Research & Reviews  2,990 results

An evaluation of asciminib for patients with chronic myeloid leukemia previously treate...
https://doi.org/10.1080/17474086.2022.2080049
Expert Review of Hematology; García-Gutiérrez V, Hernández-Boluda JCA

May 19th, 2022 - : To date, five tyrosine kinase inhibitors (TKIs) are available for treating chronic myeloid leukemia (CML) patients in clinical practice. Despite this, a significant proportion of patients will ultimately develop failure to approved TKIs due to i...

Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chro...
https://doi.org/10.2174/1871520622666220513114205
Anti-cancer Agents in Medicinal Chemistry; Donmez AC, Olgen S et. al.

May 17th, 2022 - Src family tyrosine kinases play a potential role in Bcr-Abl induced leukemogenesis. Src kinase inhibitors are reported as selective inhibitors of chronic myeloid leukemia. Since there is an inhibitive effect of Src kinase inhibitors on chronic my...

Combinational treatment of TPEN and TPGS induces apoptosis in acute lymphoblastic and c...
https://doi.org/10.1007/s12032-022-01697-w 10.1590/1414-431X20165426 10.1016/s1470-2045(19)30031-2 10.3324/haematol.2020.247031 10.3324/haematol.2015.131680 10.1182/blood.2019004043 10.12659/MSM.923271 10.1146/annurev.immunol.22.012703.104753 10.1002/ajh.25792 10.1517/14656566.2011.533169 10.21873/anticanres.14215 10.3390/cancers13194820 10.1007/s10495-017-1375-1 10.1038/s41418-017-0012-4 10.1007/s00018-016-2209-y 10.1177/2211068216681979 10.3389/fonc.2019.00665 10.3390/jcm10163556 10.1093/nar/gkab438 10.1146/annurev-cancerbio-041916-065808 10.1155/2015/294303 10.1007/s10495-017-1424-9 10.1155/2019/5381692 10.1038/s12276-020-0384-2 10.1155/2012/313275 10.1007/s10534-020-00262-0 10.1007/s10534-017-0015-0 10.1007/978-981-15-4501-6_45-1 10.1016/j.ijpharm.2017.01.020 10.1007/s10495-016-1266-x 10.1155/2021/5580288 10.1021/acs.chemrestox.8b00138 10.1002/0471141755.ph0919s72 10.3389/fphar.2019.01222 10.1016/j.bbrc.2004.03.110 10.1007/978-981-10-6583-5_1 10.1007/s11914-017-0378-8 10.1182/blood-2017-12-784132 10.1038/s41375-021-01248-8 10.1182/blood.2018882233 10.3390/cancers13040669
Medical Oncology (Northwood, London, England); Mendivil-Perez M, Jimenez-Del-Rio M et. al.

May 17th, 2022 - TPEN and TPGS have recently shown selective cytotoxic effects in vitro and ex vivo leukemia cells. In this study, we aimed to test the synergistic effect of combined TPEN and TPGS agents (thereafter, T2 combo) on Jurkat (clone-E61), K562, Ba/F3, a...

Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - Wha...
https://doi.org/10.1016/j.blre.2022.100968
Blood Reviews; Lipton JH, Brümmendorf TH et. al.

May 16th, 2022 - The development of BCR::ABL1-targeting tyrosine kinase inhibitors (TKIs) has improved the prognosis of patients with chronic myeloid leukemia (CML). Although there are some common class-wide side effects, differences in safety profiles between TKI...

Alterations in cellular metabolisms after Imatinib therapy: a review.
https://doi.org/10.1007/s12032-022-01699-8 10.1186/s13045-019-0729-2 10.1007/s12032-021-01462-5 10.21276/apjhs.2018.5.4.12 10.1186/s13045-018-0624-2 10.1016/S0959-8049(02)80603-7 10.1016/j.leukres.2003.10.003 10.1634/theoncologist.12-12-1390 10.1111/j.1600-0609.2011.01689.x 10.1182/asheducation-2013.1.168 10.1080/17474086.2017.1339599 10.1016/j.ccell.2020.03.006 10.1007/s11010-022-04376-6 10.2165/00129785-200505050-00002 10.1038/cddis.2013.60 10.1126/science.124.3215.267 10.1016/j.cmet.2007.10.002 10.1101/gad.1529107 10.1097/01.mco.0000232894.28674.30 10.1038/nrm3025 10.1016/j.cmet.2008.07.007 10.1038/emm.2015.122 10.1111/apha.13360 10.1016/j.molmet.2019.08.001 10.1158/1078-0432.CCR-08-3291 10.1038/sj.onc.1208461 10.3109/10428194.2016.1142086 10.1158/1078-0432.CCR-04-0039 10.1074/jbc.M105796200 10.1016/j.cellbi.2006.08.006 10.1073/pnas.0501758102 10.1073/pnas.0810246105 10.2337/db08-0080 10.1001/jama.2009.976 10.1210/jc.2010-0086 10.1182/blood.V124.21.1813.1813 10.1016/j.cmet.2006.06.003 10.1530/JME-12-0003 10.1074/jbc.M109.085084 10.1146/annurev-ento-112408-085356 10.1155/2016/5415767 10.1007/978-90-481-8622-8 10.1038/nrc2222 10.1161/01.ATV.0000124105.39900.db 10.18632/oncotarget.5580 10.1016/j.leukres.2009.02.024 10.3324/haematol.11680 10.1056/NEJMc052500 10.1056/NEJMoa1609324 10.1080/10428194.2016.1228928 10.1038/sj.bjc.6604946 10.1007/s00018-015-2070-4 10.3389/fcell.2020.603837 10.1038/s12276-020-0375-3 10.1016/j.tibs.2014.02.004 10.1074/jbc.R112.357194 10.1038/bjc.2013.293 10.1016/j.trecan.2016.06.002 10.1002/cncr.20057 10.1158/0008-5472.CAN-06-2519 10.1158/1535-7163.MCT-08-0589 10.1038/cgt.2016.28 10.1080/00365521.2016.1190399 10.1038/nm934 10.1186/s12943-018-0798-9 10.1089/omi.2020.0144 10.1089/omi.2012.0012 10.1016/j.pharmthera.2010.04.012 10.1111/1567-1364.12094 10.1016/j.bbagen.2012.09.008 10.1038/ncb3389 10.1016/j.micres.2014.04.003 10.1146/annurev.nutr.012809.104810 10.3390/ijms21010088 10.18632/aging.202962 10.1586/era.11.175 10.1007/BF00686113 10.1182/blood.V96.3.925 10.1038/sj.onc.1206620 10.1182/blood-2004-10-3864 10.3892/mmr.2017.7952 10.1016/j.bcp.2018.07.001 10.3389/fphar.2020.01106 10.1016/j.bbrc.2021.03.166
Medical Oncology (Northwood, London, England); Kumar V, Singh P et. al.

May 16th, 2022 - Chronic myeloid leukemia (CML) is characterized by the possession of the Philadelphia chromosome, which contains the Bcr-Abl oncogene that codes for the oncoprotein BCR-ABL. Through glucose metabolism, glycolysis, and the translocation of the high...

see more →

Guidelines  4 results

Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2020.0047
Journal of the National Comprehensive Cancer Network : JN... Deininger MW, Shah NP et. al.

Oct 7th, 2020 - Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to a BCR-ABL1 fusion gene. CML occurs in 3 different phas...

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendati...
https://doi.org/10.1002/cncr.31411
Cancer Rea D, Ame S et. al.

May 4th, 2018 - The ultimate goal of chronic myeloid leukemia management in the tyrosine kinase inhibitor (TKI) era for patients who obtain deep molecular responses is maintaining a durable off-treatment response after treatment discontinuation; this situation is...

Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment an...
https://doi.org/10.1093/annonc/mds228
Annals of Oncology : Official Journal of the European Soc... Baccarani M, Pileri S et. al.

Nov 20th, 2012 - Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2012|Baccarani M,Pileri S,Steegmann JL,Muller M,Soverini S,|therapeutic use,diagnosis,drug therapy,genetics,therapeutic use,

Chronic myeloid leukemia: an update of concepts and management recommendations of Europ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979100
Journal of Clinical Oncology : Official Journal of the Am... Baccarani M, Cortes J et. al.

Nov 4th, 2009 - To review and update the European LeukemiaNet (ELN) recommendations for the management of chronic myeloid leukemia with imatinib and second-generation tyrosine kinase inhibitors (TKIs), including monitoring, response definition, and first- and sec...

see more →

Drugs  50 results see all →

Clinicaltrials.gov  86 results

A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
https://clinicaltrials.gov/ct2/show/NCT05367765

May 10th, 2022 - The purpose of this study is to investigate the long-term efficacy and safety of Flumatinib versus Imatinib in newly diagnosed CML-CP patients to the provide the real world evidence for the clinical treatment of CML-CP in China. The overall design...

A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.
https://clinicaltrials.gov/ct2/show/NCT05367700

May 10th, 2022 - This is an open-label, multicenter, dose-escalation and expansion, first-in-human study in participants of CML with T315I mutation or without T315I mutation in chronic phase/accelerate phase(CP/AP). This study will consist of two parts: A part 1 d...

Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia
https://clinicaltrials.gov/ct2/show/NCT03817398

May 3rd, 2022 - PRIMARY OBJECTIVES: I. To determine the 2-year treatment free remission (TFR) rate of children, adolescents, and young adults with chronic myeloid leukemia - chronic phase (CML-CP) following discontinuation tyrosine kinase inhibitor (TKI). II. To ...

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
https://clinicaltrials.gov/ct2/show/NCT04925479

Apr 26th, 2022 - The aim of this study is to support development of asciminib in the pediatric population (1 to <18 years) with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (PH+ CML-CP) previously treated with one or more Tyrosine kin...

A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
https://clinicaltrials.gov/ct2/show/NCT05304377

Apr 22nd, 2022 - This first-in-human trial with ELVN-001 is a dose escalation study whose primary purpose is to identify the recommended dose for expansion RDE of single agent ELVN-001 in chronic phase or accelerated phase CML with and without T315I mutations. The...

see more →

News  445 results

2021 Approvals Expand Access to Care for Patients Across Tumor Types
https://www.onclive.com/view/2021-approvals-expand-access-to-care-for-patients-across-tumor-types

Mar 10th, 2022 - Last year marked the 50th anniversary of the National Cancer Act of 1971, a landmark legislation that committed to funding biomedical research, establishing oncology training programs, and building a nationwide network of cancer treatment centers....

Gerds Takes a Closer Look at Treatment Sequencing in Hematologic Malignancies
https://www.onclive.com/view/gerds-takes-a-closer-look-at-treatment-sequencing-in-hematologic-malignancies

Feb 16th, 2022 - Disease risk, disease burden, and duration of treatment, as well as the reason for progression and generation of the drug are being used to tailor treatment sequencing strategies in hematologic malignancies where treatments are abundant, explained...

What to Know About Polycythemia Vera and Treatment Options
https://www.onclive.com/view/what-to-know-about-polycythemia-vera-and-treatment-options

Jan 25th, 2022 - Ruben Mesa, MD: Pivoting back with earlier disease, Angela, why don’t you walk us through the diagnosis and kind of initial assessment of polycythemia vera [PV]? Angela Fleischman, MD, PhD: Many times, someone or a hematologist will be referred...

CML: Asciminib Use in Later-Line Chronic Myeloid Leukemia
https://www.onclive.com/view/cml-asciminib-use-in-later-line-chronic-myeloid-leukemia

Jan 23rd, 2022 - Transcript: Daniel J. DeAngelo, MD, PhD: Asciminib, or ABL001 as it was previously known, is a newer agent. It has a different mechanism of action; I think it’s important to highlight that. Asciminib differs from all the other approved tyrosine k...

see more →

Patient Education  3 results see all →